Highlight
This phase 2 clinical trial evaluates the efficacy of rituximab in combination with either pentostatin or bendamustine in patients with multiply relapsed or refractory hairy cell leukemia (HCL) or variant HCLv, achieving overall response rates significantly higher than rituximab monotherapy. Both regimens demonstrate promising complete remission and progression-free survival outcomes, though baseline imbalances render direct superiority conclusions tentative. The findings suggest these combinations as potent therapeutic options for heavily pretreated HCL/HCLv patients.
